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Protein ubiquitination is of great cellular importance through its central role in
processes such as degradation, DNA repair, endocytosis and inflammation.
Canonical ubiquitination takes place on lysine residues, but in the past
15 years non-lysine ubiquitination on serine, threonine and cysteine has
been firmly established. With the emerging importance of non-lysine ubiqui-
tination, it is crucial to identify the responsible molecular machinery and
understand the mechanistic basis for non-lysine ubiquitination. Here, we
first provide an overview of the literature that has documented non-lysine
ubiquitination. Informed by these examples, we then discuss the molecular
mechanisms and cellular implications of non-lysine ubiquitination, and
conclude by outlining open questions and future perspectives in the field.1. Introduction
1.1. The ubiquitin–proteasome system
Ubiquitin is a 76-amino-acid polypeptide that is highly conserved among
eukaryotes. The covalent attachment of ubiquitin, namely ubiquitination, plays
a crucial role in many biological pathways, such as DNA damage repair,
signal transduction, inflammatory response generation, endocytosis, transcrip-
tional regulation and cell-cycle progression [1]. Perhaps the best-studied
purpose of ubiquitin attachment, however, is to signal for proteasome-mediated
protein degradation. In this so-called ubiquitin–proteasome system (UPS),
attachment of ubiquitin moieties targets substrate proteins for degradation by
the 26S proteasome, a 2.5-MDa molecular machine that first recognizes substrates
through their ubiquitin modification; this is followed by substrate deubiquitination,
unfolding and ultimately degradation in a central proteolytic chamber.
The 26S proteasome consists of the 20S proteolytic core and two attached
19S regulatory complexes. The regulatory complexes recognize ubiquitinated
substrates using ubiquitin receptors, i.e. ubiquitin-interacting proteins. The
19S cap also contains two (Saccharomyces cerevisiae) or three (most other eukar-
yotes) deubiquitinating enzymes (DUBs); over 100 DUB-encoding genes have
been predicted in the human genome to date [2,3]. Ubiquitin is synthesized
as an inactive precursor of multiple ubiquitin units, and DUBs play an impor-
tant function in cleaving the precursor to release free ubiquitin [4]. In the
context of the proteasome, DUB-catalysed removal of substrate ubiquitin
units permits ubiquitin to be recycled for further use. Moreover, ubiquitin
removal by DUBs may provide a last-minute opportunity for a protein to
escape degradation [5,6]. Following ubiquitin removal, the substrate protein
is unfolded by a ring of AAA (ATPases Associated with diverse cellular Activi-
ties) ATPases located at the entry of the proteolytic core. Finally, the unfolded
polypeptide chain is threaded through a narrow channel into the central
cavity of the 26S proteasome, where proteases ensure its efficient cleavage
into peptides [6,7].
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21.2. The ubiquitination process
Ubiquitination occurs through the sequential action of three
enzyme classes: ubiquitin-activating (E1), ubiquitin-conjugat-
ing (E2) and ubiquitin ligase (E3). Upon processing of the
ubiquitin precursor by DUBs that cleave specifically after
the C-terminal Gly75-Gly76 motif, Gly76 is exposed and
poised to react. Ubiquitin becomes ‘activated’ when an E1
enzyme uses the energy supplied by ATP hydrolysis to gen-
erate a thioester bond between its active-site cysteine
residue and the C-terminus of ubiquitin. In the next step, ubi-
quitin is transferred onto the active-site cysteine of an E2
enzyme (figure 1a). The charged E2 finally interacts with an
E3 ligase that facilitates positioning and transfer of ubiquitin
onto the substrate by one of several mechanisms dependent
on the class of E3 enzyme (see below) [8]. Irrespective of
the class of E3 enzyme, however, it is the E3 that determines
substrate recognition and thus specificity in the system.
1.3. E2 enzymes and E3 ligases: a brief overview
E2 enzymes (of which approx. 40 have been found in the
human proteome) are characterized by a conserved core
region of approximately 150 amino acid residues. This
region accounts for the enzymatic activity of the E2s due to
a catalytic cysteine residue and is referred to as the ubiqui-
tin-conjugating (UBC) domain. In the cell, E2s primarily
exist as E2-ubiquitin conjugates (figure 1a), prone to ubiquiti-
nate their substrates [9–11]. However, E2-ubiquitin conjugates
show low rates of ubiquitin transfer in the absence of an E3
enzyme [10]. Binding studies of E2-E3 pairs have recently
shown that E2s have a markedly higher affinity for their
cognate E3 when the E2 is conjugated to ubiquitin [12].
E3 enzymes are by far the most numerous enzyme family
in the ubiquitination cascade, represented by approximately
700 enzymes in mammals. E3s are classified into subfamilies
according to the presence of either a RING (Really Interesting
New Gene) finger or a HECT (Homologous to the E6AP Car-
boxyl Terminus) domain. E3 ligases of the RING finger
family can simultaneously bind ubiquitin-charged E2 and
substrate, and thus facilitate the direct transfer of the
ubiquitin moiety onto the substrate. On the other hand, the
non-RING E3 ligases of the HECT type, as well as
the RING-between-RING (RBR)-type ligases, constitute a
molecular stepping stone for the ubiquitin molecule through
a covalent interaction with an active-site cysteine of the E3
enzyme [13,14]. By this mechanism, ubiquitin is transferred
from the E2 to the E3 and from here onto specific substrate
acceptor sites [15,16].
1.4. Ubiquitin linkage types can determine substrate
fate
Sequential rounds of ubiquitination yield polyubiquitinated
protein substrates. During ubiquitin chain elongation, the car-
boxyl group of the C-terminal Gly76 within the preceding
ubiquitin molecule is linked via an isopeptide bond to one
of the seven lysine residues (Lys6, Lys11, Lys27, Lys29,
Lys33, Lys48 or Lys63) of the subsequent ubiquitin moiety.
Furthermore, head-to-tail ubiquitin conjugation occurs,
where the C-terminal Gly76 of the proximal ubiquitin mol-
ecule is linked to the N-terminal amino group of Met1 ofthe distal ubiquitin via a regular peptide bond [1,17]. Ubiqui-
tin chains can be homotypic (involving the same lysine
residue), heterotypic (involving different lysine residues in
one chain) or branched, where a ubiquitin molecule is further
ubiquitinated on different lysine residues.
It has been generally accepted that Lys48-linked polyubi-
quitin chains of four ubiquitin moieties or more are required
for proteasomal degradation [18]. However, other chain topol-
ogies can mediate degradation. Studies of S. cerevisiae have
shown that Lys11 linkages preferentially modify a subset of
protein substrates and play an important role in endoplasmic
reticulum-associated degradation (ERAD; §2.1). Additionally,
it has been shown that branched Lys11/Lys48-linked chains
provide a better signal for degradation by the proteasome
than do non-branched chains [19]. Even monoubiquitina-
tion on one or more sites can be sufficient for proteasomal
recognition and degradation [20,21].
1.5. Non-lysine ubiquitination
For many years, lysine was considered the only site for sub-
strate ubiquitination, and it is still considered the canonical
ubiquitination site. However, it is now established that
cysteine, serine and threonine residues, as well as the free
amino group of the N-terminus of proteins, also function as
sites for ubiquitination, forming thioester, hydroxyester and
peptide bonds, respectively (figure 1a) [22]. Although the
tyrosine side chain is also hydroxylated, like serine and threo-
nine, no examples of ubiquitination occurring on tyrosine
exist to date. This may not be surprising, given the presence
of the benzene ring, leaving the oxygen lone pairs less reac-
tive that those on serine or threonine. Finally, some bacteria
have evolved a ubiquitination mechanism, carried out by
proteins of the SidE effector family, that results in phospho-
ribosyl-linked ubiquitin conjugated to serine residues of the
protein substrate (figure 1b) [23]. In this review, we focus
on non-lysine ubiquitination as it pertains to the conjugation
of ubiquitin to the side chains of cysteine, serine or threonine,
and not on the N-terminal ubiquitination of a substrate or
ubiquitination performed by the SidE effectors.
The conjugates generated from ubiquitination on non-
lysine residues are thermodynamically less stable than the
ones generated on lysine residues. This raises interesting
questions concerning their different physiological functions
(§§4.1 and 4.2), which may be governed in part by differences
in reaction kinetics.
The thioester bond generated from conjugating ubiquitin
onto a cysteine residue is the least stable bond that forms
between ubiquitin and a substrate protein. As described
above, ubiquitin is transferred from an E1 onto an E2
enzyme and finally (via an E3 enzyme in the case of non-
RING-type E3s) onto the substrate. Thus, intermediate
ubiquitin-E1/E2/E3 conjugates are linked via a thioester
bond formed between Gly76 of ubiquitin and a cysteine resi-
due of the enzyme. Because the sulfur lone pair is a soft
nucleophile that reacts preferentially with soft electrophiles,
the reaction with a thioester carbonyl (i.e. the electrophile of
the thioester linkage on the E2) is faster than the reaction of
a hydroxyl, which is, in turn, faster than the reaction of an
amine group with the E2 thioester carbonyl [24]. Therefore,
even if ubiquitination on a cysteine residue results in a rela-
tively weak bond, this thioester bond is readily formed. In
signalling events where a rapid response is required, this
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Figure 1. Schematic overview of canonical and non-canonical ubiquitination. (a) The lone pair of a substrate nucleophile, X, representing lysine/N-terminal amines,
cysteine thiols or serine/threonine hydroxyls, attacks the electrophile thioester carbonyl of an E2-ubiquitin (Ub) conjugate. This results in a Ub-substrate conjugate
linked by an isopeptide (lysine), peptide (N-terminal), thioester (cysteine) or hydroxyester bond (serine/threonine), respectively. Here, we focus on non-lysine ubi-
quitination defined as conjugation of Ub on the side chains of cysteine, serine or threonine (as indicated by the box). (b) Ubiquitin conjugated to a substrate as a
result of ubiquitination mediated by SidE effector proteins. A phosphoribosyl links Arg42 of Ub to a substrate serine residue.
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3type of ubiquitination may be preferable. Physiologically, the
combination of lysine and non-lysine ubiquitination endows
the UPS with greater flexibility.2. Non-lysine ubiquitination targets a
variety of cellular processes
Previous reviews have provided thoughtful insight into non-
lysine ubiquitination based on the literature known at the
time [24,25]. First identified as an activity of virus-encoded
E3 ligases affecting the stability of components of the
human immune system [26–28], the process has since been
demonstrated in yeast and at various cellular locations. More-
over, examples of non-lysine ubiquitination actors and
substrates are rapidly increasing. Below, we review the exist-
ing literature on non-lysine ubiquitination (with the focus
defined above), organized according to the cellular processes
involved. Table 1 summarizes known substrates, as well as
E2 and E3 enzymes implicated in non-lysine ubiquitination.2.1. Endoplasmic reticulum-associated degradation
(ERAD)
Much of the crucial information about non-lysine ubiquitina-
tion has been obtained from studies of ERAD [55]. When
folding or oligomeric assembly of proteins in the ER goes
awry, misfolded proteins accumulate [56]. Aberrant proteins
are first recognized by ER chaperones and/or specific
ERAD factors. They are then targeted to the cytosol in aprocess termed dislocation that involves a channel through
which the substrate is retrotranslocated. Once an ERAD sub-
strate reaches the cytosolic side of the ER membrane,
membrane-embedded E3 ligases work together with E2
enzymes to effect polyubiquitination. Finally, the 26S protea-
some degrades the protein. Several viruses usurp the ERAD
system to avoid immune detection, often by targeting impor-
tant molecules of the immune system, such as the major
histocompatibility complex (MHC) class I heavy chain
(HC), for degradation. While this degradation is initiated at
the ER membrane in ERAD, MHC-I HC can also undergo
ubiquitination-dependent endocytosis at the plasma mem-
brane followed by lysosomal degradation (see §2.3). Not
only viruses exploit the ERAD pathway for their own
purposes—a range of AB-type toxins, such as cholera, ricin
and pertussis, use the ERAD pathway to gain access to the
cytosol, where they perform their deleterious functions
([57]; §4.1).2.1.1. MHC class I heavy chain and CD4
The first known example of an ERAD substrate modified by
non-lysine ubiquitination was MHC-I HC. The mouse γ-her-
pesvirus protein, mK3, is an E3 ligase that directs MHC-I HC
for degradation in infected cells. The C-terminal cytosolic tail
of MHC-I HC, a type I transmembrane protein, contains both
lysine and serine residues. Early work showed that although
this cytosolic tail is required for degradation of the protein,
degradation of a mutant of MHC-I HC with all tail lysines
replaced by arginines proceeded efficiently in cells expressing
mK3 [58]. While these findings may be explained by a model
Table 1. Overview of the literature documenting non-lysine ubiquitination, with a focus on internal cysteine, serine and/or threonine residues. ND, not
determined. Notations in the ‘modiﬁed residues’ column convey the following: ‘Non-Lys’ indicates that the ubiquitination could be N-terminal, or on an internal
non-lysine residue (cysteine, serine and threonine); e.g. a lysine-free version of the substrate was still degraded, but no further experimental evidence regarding
what residue(s) is/are ubiquitinated was provided. ‘Not N-terminal’ indicates that N-terminal ubiquitination was ruled out experimentally. ‘Lys/Cys/Ser/Thr’
(in various combinations) indicates that there is indirect (i.e. mutation of other residue(s) does not prevent ubiquitination and/or degradation), semi-direct
(i.e. ubiquitination sensitive to reducing agents or alkaline treatment) or direct (mass spectrometry) evidence that ubiquitination can occur on those residues. If
known, preference for certain residues over others is indicated. The ± designation indicates that a substrate was tested both in its native state (with endogenous
lysines or N-terminus available) and in a recombinant form (with endogenous lysines mutated to arginines or the N-terminus chemically blocked, for example).
E2(s) E3(s) substrate(s) modiﬁed residue(s) process reference(s)
ND Mir1/kK3 Lys-free MHC-I
HLA.B7
Lys/Cys-free MHC-I
HLA.B7
non-Lys, Cys
non-Lys, non-Cys
virus-induced
endocytosis/
degradation
[26]
ND mK3 MHC-I HC ± Lys
MHC-I HC ± N-Ub
Ser/Thr virus-induced ERAD [27]
Ube2J2 mK3 MHC-I HC variants preferential Ub of
Ser/Thr
virus-induced ERAD [28]
ND SCFβ-TrCP
(cellular) with
Vpu (viral)
CD4 Lys/Ser/Thr (Cys not
investigated)
virus-induced ERAD [29,30]
ND ND Lys-free TCRα non-Lys ERAD [31]
Ube2G2 ND Lys-free TCRα non-Lys ERAD [32]
ND HRD1 TCRα Ser267, Ser268
(Cys, Lys, Thr are
able to substitute)
ERAD [33]
ND HRD1 (for all
variants)
NS-1 κ LC variants Ser/Thr preferred over
Lys; not N-terminal;
non-Cys
ERAD [34]
ND HRD1 mini-HC and NHK
α1-anti-trypsin
Ser/Thr ERAD [34]
ND HRD1 (± Lys) TCRα ± Lys non-Lys; non-Cys;
not N-terminal
ERAD [35]
ND ND neutrophil elastase
(naturally Lys-free)
non-Lys ERAD [35]
Ube2J1 HRD1 (±Lys) MHC-I HC ± Lys Lys preferred over
Ser/Thr
ERAD [36]
Ubc6/Ubc7
(Ube2J2/
Ube2G2
homologues)
DOA10
(MARCH6
homologue)
Vma12
Sbh2
Ubc6
Ubc6 mono-Ub
Lys/Ser*/Thr
ERAD [37]
*Ub shown by
mass spec
ND ND SM/SQLE
(N100 degron)
non-Lys regulated ERAD [38]
Ube2j2 MARCH6 SM/SQLE
(N100 degron)
Ser59, Ser61, Ser83*,
Ser87
regulated ERAD [39]
*Ub shown by
mass spec
ND ND Bid-N (Lys-free
amino terminus)
Cys, Ser/Thr;
not N-terminal
regulated
degradation
[40]
ND ND N-terminally blocked,
Lys-free neurogenin2
Cys, Ser/Thr regulated
degradation
[41]
(Continued.)
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Table 1. (Continued.)
E2(s) E3(s) substrate(s) modiﬁed residue(s) process reference(s)
ND ND N-terminally blocked,
Lys-free
neurogenin3
Cys, Ser/Thr regulated
degradation
[42]
dBRUCE ND reaper ± Lys non-Lys regulated
degradation
[43]
Ubc6/Ubc7
(Ube2J2/Ube2G2
homologues)
DOA10
(MARCH6
homologue)
Asi2 ± Lys Ser/Thr in Lys-free,
Lys preferred in WT
regulated
degradation
[44]
ND ND NY-ESO-1 antigen ±
Lys
Ser/Thr, not N-terminal antigen processing/
presentation
[45]
Ube2D1 ND Lys-free MARCH1 non-Lys regulated
endocytosis
[46]
Ube2D1 Ube2D3
Ube2E1
MYCBP2/Phr1 Free amino acids;
pentapeptides
E3 prefers Thr over Ser in vitro [47]
ND MYCBP2/Phr1 NMNAT2 Ser/Thr, non-Cys in vitro [47]
Pex4 (Ubc10) ND S. cerevisiae Pex5
(N-terminally
blocked, Lys-free)
Cys6 peroxisomal signal
receptor recycling
[48]
ND ND mammalian Pex5 Cys11 peroxisomal signal
receptor recycling
[49]
UbcH5a
UbcH5b
UbcH5c
ND mammalian Pex5 Cys11 peroxisomal signal
receptor recycling
[50]
Pex4 (Ubc10) Pex12 S. cerevisiae Pex5 Cys6 peroxisomal signal
receptor recycling
[51]
ND ND S. cerevisiae Pex18 Cys6 peroxisomal signal
receptor recycling
[52]
Pex4 (Ubc10) Pex10, Pex12 S. cerevisiae Pex18 Cys6 peroxisomal signal
receptor recycling
[53]
Pex4 Pex2, Pex10,
Pex12
P. pastoris Pex20
(Pex18 homologue)
Cys8 peroxisomal signal
receptor recycling
[54]
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5whereby partial dislocation of the ectodomain would result
in its ubiquitination upon exposure to the cytosol, subsequent
work demonstrated that MHC-I HC entirely devoid of lysines
was still ubiquitinated and efficiently degraded [27]. More-
over, it was shown that mK3 could facilitate ubiquitination
of a single serine, threonine or lysine (but not cysteine) resi-
due placed close to the C-terminus of the cytosolic tail of
MHC-I HC, resulting in its efficient degradation [27]. These
surprising findings were extended to show that, even in the
context of the native sequence, serine residues were pre-
ferentially ubiquitinated over lysine residues in a reaction
catalysed by the E2 Ube2j2, a tail-anchored ER membrane
protein, which was shown to be the cognate E2 of mK3
[28]. Thus, despite the presence of several lysine residues in
the MHC-I HC tail region, ubiquitin was primarily conju-
gated to serine/threonine residues, as judged by the
notable loss of ubiquitinated species upon NaOH treatment.This experimental procedure is used to probe for serine/
threonine ubiquitination, due to the alkaline sensitivity of
the relatively labile hydroxyester bond. In similar work,
both lysine and serine/threonine residues in the cytosolic
tail of the immune receptor CD4 can be ubiquitinated and
contribute to the ERAD of CD4 in cells expressing Vpu, an
accessory type I integral membrane protein expressed by
HIV-1 [29]. To accomplish the rapid degradation of CD4 mol-
ecules from the ER membrane, Vpu recruits a cellular E3
ligase complex, SCFβ-TrCP [29].
The human cytomegalovirus encodes two proteins, US2
and US11, that induce rapid cellular degradation of MHC-I
HC molecules although neither is an E3 ligase [59]. Like
mK3-mediated degradation, US11-mediated degradation of
lysine-free MHC-I HC proceeds efficiently, indicating non-
lysine ubiquitination [60]. While non-lysine ubiquitination
of the MHC-I HC cytosolic tail was not directly
royalsocietypublishing.org/journal/rsob
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6demonstrated, recent work identified that a previously
uncharacterized E3 ligase, TMEM129, uses Ube2j2 as its cog-
nate E2 in the US11-mediated degradation of MHC-I HC
[61,62]. In addition, another E2 enzyme, Ube2k, was shown
to be important for ubiquitination [62]. Taken together,
these data are compatible with a model where TMEM129
recruits Ube2j2 to facilitate ubiquitination on serine and/or
threonine residues on the cytosolic tail of MHC-I HC. More-
over, it was suggested that Ube2j2 functions to initiate
substrate ubiquitination, whereas Ube2k, which itself is not
able to initiate ubiquitination, extends the monoubiquitinated
substrate with Lys48-linked ubiquitins [62,63].
2.1.2. T-cell receptor complex
Another protein of the immune system, the α-subunit of the
T-cell receptor complex (TCRα), is an important model sub-
strate in ERAD studies. This stems from the finding that,
when present in stoichiometric excess of its companion sub-
units, TCRα is rapidly degraded [64]. In analogy to the
studies on MHC-I HC, early work showed that lysine-free
TCRα is efficiently degraded in a proteasome-dependent
manner [31]. In a stable isotope labelling in cell culture
approach, lysine-free TCRα was shown to be ubiquitinated
on serine/threonine residues as judged by sensitivity to alka-
line treatment, although mass spectrometry (MS) did not
succeed in identifying the modified residues [35]. By contrast,
three specific ubiquitinated lysine residues were identified
in the wild-type protein, which did not show evidence of
non-lysine ubiquitination.
This result seemingly contrasts the finding that two con-
served serine residues present at the very C-terminal end of
the short cytosolic tail of TCRα mediate ubiquitination and
ERAD of the protein [33]. In mutational studies, it was
found that substitution of the two serines with alanine resi-
dues almost completely prevented ubiquitination and
stabilized TCRα. Conversely, insertion of additional serine
residues in the tail region increased ubiquitination as well
as the kinetics of degradation. Finally, replacement of the
two serine residues with threonine, cysteine or lysine residues
still allowed ubiquitination and fast degradation. While the
formal possibility exists that the serine-mediated TCRα
degradation may be an indirect effect of the serine residues
promoting ubiquitination of other residues in the protein,
the most likely explanation is direct ubiquitination of these
residues. Concerning the involved ubiquitination machinery,
the E3 ligases Hrd1 [33,35] and gp78 [65] have been shown
to mediate TCRα ubiquitination, whereas E2 enzymes
Ube2j1 [66], Ube2j2 [66] and Ube2g2 [32,65] have all been
implicated in the process. Notably, unassembled TCRα
chains have been demonstrated not to integrate efficiently
into the membrane, but instead localize to the ER lumen
[67]. In essence, these chains can, therefore, be considered
as soluble ERAD substrates (see below). It is interesting to
note that the two very C-terminal (serine) residues become
ubiquitinated, indicating that this substrate is likely to be ret-
rotranslocated with the C-terminus first and ubiquitinated as
soon as it enters the cytosol.
2.1.3. Soluble ERAD substrates
All examples above involve transmembrane proteins with
non-lysine ubiquitination occurring on the cytosolic portionof the targeted molecule. However, there is evidence that
the soluble ERAD substrate non-secreted immunoglobulin κ
light chain (NS-1 κ LC) is also extensively ubiquitinated on
serine/threonine residues [34]. Using NaOH treatment, it
was established that NS-1 κ LC is mainly ubiquitinated on
serine and threonine residues. However, lysine residues are
also modified since polyubiquitination was only reduced
substantially when mutating all serines, threonines and
lysines, correlating with significant cellular stabilization of
only this mutant. Moreover, two other soluble ERAD sub-
strates were also found to contain ubiquitination that was
labile under alkaline conditions [34]. As observed for both
TCRα and MHC-I HC [33,35,36], Hrd1 activity was critical
for ubiquitination and degradation of the three soluble
ERAD substrates tested.
2.2. Regulated degradation
Regulated protein degradation by the UPS is essential to pre-
cisely control levels of proteins during development and
differentiation, as well as in central cellular processes such
as cell-cycle control or regulation of metabolism and biosyn-
thesis. Below are examples of non-canonical ubiquitination in
pathways that rely on a finely tuned balance between protein
components.
2.2.1. Cholesterol biosynthesis
Cholesterol homeostasis and biosynthesis are governed in part
by two rate–limiting enzymes: 3-Hydroxy-3-Methylglutaryl-
CoA Reductase (HMGCR) and squalene monooxygenase
(known as SQLE or SM) [68]. SQLE stability is inversely
correlated with cellular cholesterol levels, as SQLE is subjected
to regulated ERAD when additional cholesterol synthesis is
unnecessary.
Several examples in the literature connect SQLE degra-
dation to E2 and E3 enzymes implicated in non-lysine
ubiquitination. In yeast, the SQLE homologue Erg1 exhibits
regulated degradation in response to plentiful sterols; this
requires the E2 Ubc6 and the Doa10 E3 ligase, which also par-
ticipate in non-regulatory ERAD (see §3.1.1). The replacement
of a cluster of four lysine residues with arginines resulted in
near-complete stabilization of Erg1, suggesting that alterna-
tive residues are unused or unavailable in this case [69].
The mammalian homologues of Ubc6 and Doa10, namely
Ube2j2 and membrane-associated RING finger protein 6
(MARCH6), have been linked to SQLE degradation [70–72],
but there are some clear differences. First, Erg1 residue
Lys311, determined to be the critical lysine for its degra-
dation, is not conserved in SQLE. In addition, Erg1 lacks an
N-terminal sequence known as SM N100, which serves
SQLE both as a cholesterol sensor and instability-conferring
degron [38]. Of note, the transferable SM N100 degron still
behaves as such even when all five of its lysine residues are
mutated to arginine [38]. Recently, a careful investigation of
SM N100 serine residues identified Ser59, Ser61, Ser83 and
Ser87 as critical for cholesterol-induced degradation and
provided direct MS-based evidence that Ser83 is a site for ubi-
quitination; the evidence in this study also suggests that both
MARCH6 and catalytically active Ube2j2 are important for
this process [39]. Overall, these studies support that SQLE
is capable of undergoing non-lysine-dependent degradation,
which is facilitated by Ube2j2 and MARCH6.
royalsocietypublishing.org/journal/rsob
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72.2.2. Apoptosis
Regulated degradation involving non-lysine residues is also
seen in proteins linked to apoptotic pathways. The Drosophila
protein REAPER serves as a pro-apoptotic factor for regu-
lated apoptosis during development or in response to DNA
damage. The genetically associated protein dBRUCE, which
encodes an E2 Ubc domain, was found to downregulate
REAPER levels regardless of whether its lysines were
mutated [43]; this provides a basis for the prior observation
that dBRUCE overexpression led to diminished apoptosis
even when REAPER lacked lysines [73].
A second example is the Bid protein, a Bcl-2 family
member with a normally sequestered pro-apoptotic domain.
In response to appropriate death receptor signalling pathways,
Bid is cleaved into two portions; the C-terminal region
(tBid-C) goes on to signal for apoptosis, made possible
by the ubiquitination and degradation of the inhibitory
N-terminal fragment (tBid-N), which remains associated
post-cleavage. This regulatory degradation is lysine-indepen-
dent and is not due to N-terminal ubiquitination of tBid-N.
Instead, chemical and mutational analyses suggest that ubi-
quitination both on cysteine as well as on serine/threonine
residues is critical [40].2.2.3. Neuronal degeneration
Neuronal injury may result in the detachment of an axon
from its cell body, thus necessitating its destruction; axonal
destruction is also observed in various neurodegenerative
diseases. This process requires, in part, low levels of Nicotina-
mide Mononucleotide Adenyltransferase (NMNAT2), which
is targeted for proteasomal degradation by the MYCBP2
(Myc Binding Protein 2) E3 ligase. Recent in vitro experiments
demonstrate that MYCBP2 preferentially discharges ubiqui-
tin from affiliated E2s to threonine residues, which were
favoured approximately 10-fold over serines in experi-
ments comparing the effects of free amino acids [47] (see
also §3.3). Additionally, MYCBP2-dependent ubiquitination
of NMNAT2 in vitro was largely diminished by alkaline
treatment, suggesting that this behaviour extends to actual
substrates and not only to free amino acids [47].2.2.4. Asi2
As described below in §3.1, the E2s Ubc6 and Ubc7 can work
together with the Doa10 E3 to ensure efficient degradation of
certain ERAD substrates in S. cerevisiae [37]. They also per-
form this task for lysine-free Asi2, a transmembrane protein
of the inner nuclear membrane that functions as part of a
complex responsible for the quality control of misfolded or
mislocalized inner nuclear membrane proteins [74,75].
Additionally, the Asi complex negatively regulates transcrip-
tion factors critical for responding to the presence of available
extracellular amino acids. Asi2 itself is targeted for
proteasomal degradation to alleviate this repression.
Thewild-type Asi2 sequence contains 10 lysine residues, all
exposed to the nucleus, which are efficiently ubiquitinated.
Alkaline treatment did not influence the level of wild-type
ubiquitination, indicating that non-lysine ubiquitination is
insignificant for the endogenous protein [44]. Interestingly, the
degradation of lysine-free Asi2 proceeded with similar kinetics
to the wild-type protein and the mutant protein showed robustpolyubiquitination that was sensitive to NaOH treatment. In
addition to a combined total of 42 serine or threonine residues,
Asi2 contains a single cysteine; polyubiquitination, however,
was not abrogated by reducing agent. Regarding the relevant
E2 and E3 enzymes, both wild-type and lysine-free Asi2 were
stabilized in S. cerevisiae strains deleted for Doa10, Ubc6 and
Ubc7 [44]. Whether Ubc6 and Ubc7 work in tandem during
the degradation of Asi2, as is the case in the degradation of
Sbh2 (§3.1), is presently unknown.
2.3. Virus-induced degradation via endocytosis
As mentioned above, there are numerous examples of virus-
induced degradation of cellular proteins. The primary targets
are immune system molecules en route to, or already on
duty in, the plasma membrane. In fact, the first evidence
that amino acid residues other than lysine can be ubiquiti-
nated came from studies of a viral E3 ligase and its induced
degradation of MHC-I HCs from the plasma membrane [26].
The Kaposi’s sarcoma-associated herpesvirus-encoded
Mir1/kK3 E3 could promote the degradation of lysine-free
MHC-I HC, suggested to occur via ubiquitination of a con-
served cysteine. The observed ubiquitination was sensitive
to reducing agent, indicative of a thioester bond. However,
the experiment was conducted at pH 11, which would also
affect hydroxyester bonds. Furthermore, the authors
showed that the introduction of a lysine, cysteine or serine
into a poly-glycine version of the heavy chain’s cytosolic
tail was sufficient to restore degradation [26].
Vpu, again actingwith SCFβ-TrCP (see §2.1.1), also interacts
with BST-2 (also known as tetherin or CD317), a protein that
inhibits viral egress from cells. BST-2 levels are downregulated
in response to Vpu via endocytosis and lysosomal degradation;
mutational analysis of the cytosolic tail of BST-2 found that
ubiquitination still occurred even if all lysines, serines and
threonines were mutated, although in vitro assays also demon-
strated that ubiquitination of a lysine-free version of the tail
was sensitive to alkaline treatment, suggesting that hydroxy-
ester linkages can occur [76]. This conclusion is supported by
earlier work that showed the most effective downregulation of
BST-2 depended upon a consecutive serine–threonine–serine
sequence in its cytosolic domain [77].
Taken together, the available data show that the viral
manipulation of cellular proteins that stave off successful
infection often use non-lysine ubiquitination strategies. This
includes virally encoded E3 ligases acting with cellular E2s,
or virally encoded accessory proteins that recruit cellular E3
ligases to the task (as described in §2.1.1).
2.4. Additional examples
2.4.1. Neurogenins
The neurogenins are a family of bHLH transcription factors
with roles not only in neurogenesis but also in endocrine
development of the pancreas and gut and in spermatogenesis.
While N-terminal ubiquitination is sufficient to targetXenopus
neurogenin2 (Ngn2) for degradation in both Xenopus extracts
and mammalian cells, experiments with modified versions of
Ngn2 lacking lysines and incapable of N-terminal ubiquitina-
tion identified cysteines as sites for ubiquitination [41,78].
When cysteines were also removed, however, Ngn2 was
still polyubiquitinated. Combined with the demonstration
royalsocietypublishing.org/journal/rsob
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8that alkaline treatment disrupted the observed ubiquitina-
tion, this supports that Ngn2 may also be ubiquitinated on
serine or threonine [41]. Importantly, all types of ubiquitin
conjugates were sufficient to support the proteasomal degra-
dation of Ngn2, although in perhaps more physiologically
relevant conditions the lack of N-terminus or lysine avail-
ability drastically stabilizes the protein, suggesting that they
are critically important for rapid degradation under normal
circumstances [78]. Of note, while ubiquitination on non-
lysine internal residues has also been observed for the related
protein Ngn3, cysteine ubiquitination was unable to target the
protein for degradation while, for lysine-free Ngn3, serine/
threonine ubiquitination could [42]. The identities of the cellu-
lar E2 and E3 enzymes involved in Ngn ubiquitination are
presently unknown.
2.4.2. Peroxisome import receptors
While we have previously discussed ubiquitination on
cysteines mediated by virally encoded E3 ligases (§2.3), the
first demonstrations that cellular proteins could ubiquitinate
cysteines came from studies of peroxisomal signal receptor
proteins in yeast and mammalian model systems [48,49].
The targeting of proteins for import into the peroxisomal
matrix is accomplished by two different peroxisome targeting
signals and pathways, PTS1 and PTS2, each of which has its
own specific receptor (reviewed in [79]).
Pex5, the requisite receptor for PTS1, may be polyubiqui-
tinated for proteasomal degradation when it has outlived its
useful lifespan or is defective, but is also transiently mono-
ubiquitinated for regulatory purposes at the peroxisomal
membrane. The former involves the Ubc4 E2, while the
latter is due to Pex4 (aka Ubc10), or, in mammals, to
UbcH5a, b or c isoforms (figure 2a) [50]. In addition to
using different E2s, each pathway involves ubiquitination
on different residues. While Ubc4 transfers ubiquitin to
lysine, Pex4 makes use of a conserved cysteine for ubiquitin
conjugation. This transient ubiquitin signalling seems impor-
tant for continuing Pex5 recycling and activity rather than its
degradation as cysteine ubiquitination does not affect the
stability of Pex5 [80]. While replacing the conserved cysteine
residue with lysine still permits recycling, the resultant poly-
ubiquitination increases the likelihood of degradation over
further recycling and function (figure 2b(ii)) [50,80].
In Pichia pastoris, Pex20, along with Pex7, constitutes the
signal receptor for the PTS2 pathway targeting proteins
for import into the peroxisomal matrix. Similar to what is
seen for Pex5, the functional recycling of Pex20 requires
a conserved cysteine [81], which was later confirmed to be ubi-
quitinated using Pex4 [54]. The S. cerevisiae homologue of
Pex20, Pex18, is also ubiquitinated on this conserved cysteine
by Pex4 [52,53].
The identities of the relevant E3 ligases have also been
established; peroxisome-localized RING-domain-containing
proteins appear to serve as the E3s for Pex5 ubiquitina-
tion. While all three RING peroxins, Pex2, Pex10 and Pex12,
form a heteromeric complex [82], they are capable of
distinct functions. Specifically, Pex2 and Pex10 are implicated,
along with the Ubc4 E2, in the lysine-targeted polyubiqui-
tination of Pex5, committing it for degradation [51,83].
On the other hand, Pex12 acts with the E2 Pex4 to monoubi-
quitinate Pex5, priming it for another round of recycling,
cargo binding and delivery (figure 2a) [51]. Similarrequirements for Ubc4 and the RING peroxins are observed
for Pex18 [53]. By contrast, however, Pex20 seems to require
the activity of all three RING peroxins for both its mono-
and polyubiquitination and, uniquely, Pex4 participates as
an E2 in both processes [54].
2.4.3. NY-ESO-1
The NY-ESO-1 protein is a cancer/testis antigen that contains
only a single lysine. Ubiquitinated NY-ESO-1 is degraded by
the proteasome into antigenic peptides for MHC-I presen-
tation. A recent study demonstrated that removing lysine
from NY-ESO-1 did not affect its ability to be effectively
recognized and processed by the proteasome. In addition,
the authors showed that ubiquitination of lysine-free
NY-ESO-1 was sensitive to alkaline treatment, indicating it
is occurring via hydroxyester linkages to serine and/or threo-
nine residues [45]. The promiscuous recognition and
processing of various types of ubiquitination by the protea-
some would help to ensure that antigens of various origins
and sequence, whether or not they contain lysine, can still
effectively generate peptides for immune display.
2.4.4. MARCH1
MARCH1 is an E3 ubiquitin ligase of the membrane-associ-
ated RING-CH domain family. Its expression is specific to
haematopoietic antigen-presenting cells, such as B cells and
resting dendritic cells, where it participates in the regulated
ubiquitination and endocytosis of MHC-II and CD86
immune molecules [84]. MARCH1 itself is regulated by
strong transcriptional stimulation in response to a resting
immune state, which offsets its rapid proteasomal degra-
dation. It was recently demonstrated that MARCH1 with or
without its lysine residues is ubiquitinated and degraded by
the proteasome [46]. shRNA knockdown of the E2 Ube2D1
strongly stabilized wild-type MARCH1; however, whether
this also applies to lysine-free MARCH1 was not addressed.
While the responsible E3 ligase(s) has not yet been identified,
it appears that MARCH1 itself is not responsible, or is at least
not required, as mutation of catalytic residues to disable its E3
activity did not prevent its ubiquitination [46].3. Molecular mechanisms of non-lysine
ubiquitination
The examples above demonstrate that non-lysine ubiquitination
plays an important cellular function in proteasome-mediated
degradation and signalling for proteins involved in many
different cellular processes. Still, mechanistic insight into
non-lysine ubiquitination has been trailing behind the
many observations of its occurrence, and only recently
have we begun to better understand the molecular details
of how the process takes place. To a large extent, the impor-
tance of intrinsic activity of E2 and E3 enzymes towards
specific side chains, i.e. lysine versus serine/threonine/
cysteine, how such intrinsic activity is accomplished at the
molecular level, and how the cooperation between specific
E2s and E3s helps to achieve polyubiquitination on non-
lysine residues remains unexplored. In this section, we
focus on the E2 and E3 enzymes for which at least some of
this mechanistic detail is known.
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Figure 2. Differential ubiquitination pathways influence the fate of Pex5. The figure is based primarily on work performed in S. cerevisiae [48,50,51,80]. (a) The Pex5
peroxisomal transport receptor is monoubiquitinated on a conserved cysteine (Cys6; indicated by C), enabling its release from the membrane. Upon deubiquitination
(DUB; Usp15 in S. cerevisiae, Usp9X in mammals; [50]), Pex5 is competent to bind PTS1-bearing cargo and return to the membrane. Pex5 that fails to properly
release from or recycle to the membrane is instead polyubiquitinated on nearby lysine residues (Lys18, Lys24; indicated by K) and degraded by the proteasome.
Cysteine monoubiquitination is facilitated by the E2 Pex4 (aka Ubc10; UbcH5a/b/c in humans) and the integral membrane RING E3 Pex12, while lysine polyubi-
quitination uses Ubc4/5 and RING E3s Pex2 and Pex10. (b) The effects of amino acid substitutions on Pex5 regulation. Red labelling of K and S indicates that those
are introduced substitutions in place of the naturally occurring conserved C. (i) Wild-type Pex5 gets monoubiquitinated on cysteine and functions normally. A small
amount (indicated by the dashed arrow) may partition to polyubiquitination and proteasomal degradation. (ii) The substitution of the conserved cysteine with lysine
does not affect the function of Pex5, but does result in lower steady-state levels as a result of increased propensity for polyubiquitination and degradation. (iii)
Substitution of the conserved cysteine with serine is unable to support Pex5 function and results in membrane retention, polyubiquitination and degradation. This
indicates that not any ubiquitinatable residue can functionally replace Cys6.
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93.1. The Ube2j2/MARCH6 pair promotes serine/
threonine ubiquitination
E3 ligases stimulate the activity of E2 ubiquitin-conjugating
enzymes, and dedicated E2/E3 pairs function to facilitate
specific cellular reactions [10]. For instance, Ube2j2/mK3,
but not Ube2d1/mK3, facilitate non-lysine ubiquitination
on the MHC-I HC tail region [28], whereas Ube2j1/Hrd1
preferentially ubiquitinate MHC-I on lysines [28,36]. Simi-
larly, the work on Sbh2 [37] and Asi2 [44] demonstrates
that a single E3 (Doa10) can promote ubiquitination of
both lysine and non-lysine residues depending on thesubstrate and the E2 with which it pairs up. These studies
suggest that it is at least partly the specific E2/E3
pairing that determines the preferred target site(s) for
ubiquitination.
Table 1 shows that among the examples where an E2/E3
pair is known to mediate non-lysine ubiquitination on serine
and/or threonine, Ube2j2 and MARCH6 (Ubc6 and Doa10 in
yeast) is the prevalent combination observed. In addition to
their functional interaction, overexpressed Ube2j2 and
MARCH6 have been shown to co-immunoprecipitate [70].
Given the apparent importance of the Ube2j2/MARCH6
pair, we will examine this in more detail below.
royalsocietypublishing.org/journal/rsob
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10In S. cerevisiae, recent work has shown that Ubc6 works in
tandem with Ubc7 (the yeast orthologue of metazoan
Ube2g2) in polyubiquitinating substrates of Doa10 [37]. In
cells devoid of Ubc7, a monoubiquitinated ERAD substrate
became apparent, and only in the presence of both E2s was
strong Lys48-linked polyubiquitination, mediated by Ubc7,
observed. The same conclusions were drawn based on
in vitro experiments, where it was also found that Ubc6
monoubiquitinates on a serine residue. Using a lysine-free
mutant of a known ERAD substrate, the tail-anchored Sbh2
protein that is destabilized in the absence of its interactor
Ssh1, it was also demonstrated that substrate turnover
strongly relied on Ubc6 and that polyubiquitination of this
substrate was sensitive to NaOH treatment.
This work illustrates the important common mechanism
of ubiquitin priming by one E2 enzyme followed by chain
elongation by another E2 that dictates ubiquitin chain top-
ology, as previously observed in various cellular systems
(reviewed in [10]). Thus, the Ubc6/Doa10 pair primes the
substrate by addition of a single ubiquitin molecule (e.g. on
serine), and then Ubc7/Doa10 adds sequential Lys48-linked
ubiquitin molecules to target the substrate for degradation.
As described above, the Ube2j2/TMEM129 pair has also
been suggested to prime the cytosolic tail of MHC-I HC by
serine/threonine ubiquitination prior to Lys48-linked chain
elongation by Ube2k (and an unknown E3 ligase) [62]. Fur-
thermore, it was concluded that the Ube2j2/mK3 pair also
initiates ubiquitination of the MHC-I HC tail primarily on
serine/threonine residues [28]. In this case, though, it was
found that the same E2/E3 pair is sufficient to also assemble
the Lys48-linked polyubiquitin chain.3.2. Unusual molecular features of Ube2j2 likely
determine non-lysine ubiquitination
E2s possess an intrinsic reactivity, which is currently not
known to be altered by E3s, towards the N-terminal amino
group or various amino acid side chains [10]. For instance,
E2s that work together with HECT-type E3 ligases must be
able to transfer ubiquitin to cysteine residues. For RING-
type E3 ligases, substrate ubiquitination is carried out by
the E2 enzyme, which must, therefore, have intrinsic reactiv-
ity towards its specific target(s). Using free amino acids as
nucleophiles, most investigated E2s that work with RING-
type E3s can transfer ubiquitin to both lysine and cysteine.
However, Ube2w is specific for the N-terminal amino group
[85]. It is also clear that although Ube2j2 (together with
mK3) shows a preference for serine/threonine, Ube2j2/mK3
also facilitates lysine ubiquitination [28].
Canonical E2s are characterized by a conserved His-Pro-
Asn (HPN) motif in the active site, where the Asn side
chain plays an important function in catalysis by interacting
with the active-site cysteine. Moreover, it has been proposed
that a conserved position in the catalytic cleft, referred to as
the conserved E2 Ser (S)/Asp (D) (CES/D) site, divides E2
enzymes into two subgroups: the constitutively active E2s
characterized by an aspartic acid residue in the catalytic
cleft, and the regulated E2s containing a serine residue in
the catalytic cleft, where the serine allows for activation of
the E2 enzyme by phosphorylation [86]. Generally, the
CES/D site is suggested to be important for aligning the sub-
strate lysine towards the E2 catalytic cysteine to controlubiquitination efficiency [86]. Notably, Ube2j2 is lacking
these canonical E2 signatures (HPN motif and CES/D site)
and is, moreover, unusually enriched in basic residues in
the catalytic cleft as evident from its crystal structure [87].
In addition, Ube2j2 is lacking the α-helix that follows the
CES/D site in canonical E2s. This α-helix is replaced by a
longer disordered region of unknown function in Ube2j2.
Altogether, it is likely that the unusual features of the
Ube2j2 sequence and structure help determine the activity
of the enzyme towards serine and threonine. Still, compre-
hensive biochemical and structural studies are necessary to
establish in detail how Ube2j2, and other E2s, manifest
their intrinsic activity towards non-lysine residues.
3.3. An E3 ligase with specificity for threonine
ubiquitination
While classical RING-type E3 ligases depend on an associ-
ated ubiquitin-charged E2 to transfer ubiquitin to the
substrate, HECT and RBR-type E3 ligases transfer a thio-
ester-linked ubiquitin directly onto the substrate from an
internal cysteine residue (§1.3). Surprisingly, the MYCBP2
E3 ligase was recently found to work by a previously
unknown RING-Cys-relay mechanism [47]. Here, ubiquitin
is transferred from the RING-associated E2 to a cysteine resi-
due placed on a flexible so-called mediator loop in MYCBP2
and then via intramolecular transthiolation to another E3
cysteine that mediates the final delivery to a substrate threo-
nine or serine residue. Using free amino acids or short
peptides containing a central threonine, serine or lysine resi-
due, experiments demonstrated very little lysine reactivity
and a clear preference for modification of threonine over
serine [47]. Unfortunately, cysteine was not tested as an
acceptor in these experiments. As mentioned above (§2.2.3),
the cellular MYCBP2 substrate, NMNAT2, undergoes base-
labile, thiol-resistant in vitro ubiquitination by MYCBP2,
underscoring the ability of this E3 ligase to ubiquitinate
hydroxyl groups [47].
The catalytic mechanism employed by MYCBP2 in threo-
nine ubiquitination was deduced based on the crystal
structure of a catalytic fragment in combination with bio-
chemical assays using point mutants of MYCBP2 [47]. At the
active site, a histidine residueworks as a general base to extract
the threonine hydroxyl proton to facilitate a nucleophilic attack
on the thioester-linked ubiquitin. Moreover, a cluster of three
phenylalanine residues create a hydrophobic pocket to accom-
modate the threonine Cβ methyl group, a feature likely
explaining the threonine over serine selectivity by MYCBP2.
Taken together, this study provides fascinating insight at
a detailed molecular level into the first known example of
non-lysine ubiquitination performed by an E3 ligase.4. Biological importance of non-lysine
ubiquitination
Ubiquitination on lysine residues regulates a plethora of cel-
lular processes. Why, then, has nature devised non-lysine
ubiquitination? The overall answer to this question likely
relates to the fact that non-lysine ubiquitination extends the
cell biological possibilities of the ubiquitination system
beyond those afforded by lysine ubiquitination.
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114.1. Non-lysine ubiquitination extends possibilities for
substrate degradation
From the studies described in §2 on lysine-free mutants of, for
example, Asi2 and Sbh2 [37,44], it is clear that non-lysine ubi-
quitination can ensure degradation of substrates that normally
rely on lysine-directed ubiquitination for degradation. How-
ever, based on all available data, acting as a backup system
to ensure degradation of proteins that lose their lysines
throughout evolution is hardly a physiological purpose of
non-lysine ubiquitination. Rather, the availability of ubiquiti-
nation sites on serine, threonine and cysteine serves to
extend the possibilities for ubiquitination. Thus, as previously
suggested [24,25,37], the finding that priming can take place
on residues in addition to lysine likely increases the chances
of polyubiquitination by simply creating more sites for chain
extension and thus secure more efficient substrate degra-
dation. Polyubiquitinated ERAD substrates are recognized
and extracted from the ER by the AAA ATPase p97 [88].
This protein plays a central role in ERAD by unfolding ubiqui-
tin moieties as well as the substrate protein itself to prepare it
for degradation by the proteasome [89,90]. Many sites of poly-
ubiquitin attachment will thus increase the chance of p97
recognition and thereby ensure more efficient degradation.
Whether non-lysine ubiquitination is especially important
when lysine acceptor sites are sparse in substrates is presently
unclear. In this context, it has been pointed out that several
AB-type toxins show an unusual paucity of lysines in their
sequence [91], with the PTS1 subunit of the pertussis toxin
protein being an extreme example, showing an arginine-to-
lysine ratio of 22 : 0 [92]. The suggestion that this paucity of
lysine residues is caused by an evolutionary pressure to
avoid ubiquitination, and hence degradation, is supported
by experiments that show decreased cellular activity of
these toxins when mutated to contain (additional) lysine
residues [57,92]. To the best of our knowledge, similar exper-
iments introducing additional serine, threonine or cysteine
residues have not been performed. Neither has a systematic
analysis of serine/threonine/cysteine content been published
for the AB-type toxins.
It is unlikely, though, that creating more sites for ubiqui-
tination is the only function of non-lysine ubiquitination in
degradation. Work on the cytosolic tail of TCRα has shown
that replacing the two naturally occurring serine residues
that ensure rapid degradation with lysine did not prevent
efficient degradation—in fact, ubiquitination levels and
degradation kinetics of the overexpressed protein increased
for the lysine mutant [33]. While speculative at present, this
result could indicate that, for endogenous TCRα, serine ubi-
quitination allows regulation of the degradation process
that is not possible when ubiquitination takes place on lysine.
Such regulation could be influenced by the chemical nature
of the hydroxyester versus the isopeptide bond. While the
former is chemically more labile, it may at the same time be
less sensitive to DUB hydrolysis than isopeptide bonds in ubi-
quitin–lysine conjugates [28]. To our knowledge, no DUB
capable of releasing hydroxyester-linked ubiquitin has been
identified to date. This potentially suggests that serine/threo-
nine ubiquitination may serve as a label for commitment to
degradation. Given the evidence that many viral targets are
ubiquitinated on serine or threonine residues, the absence of
hydroxyester-specific DUBs would be advantageous for thevirus and a hurdle for the host. For further consideration, if
no DUB can cleave the proximal ubiquitin moiety attached
to serine/threonine, ubiquitin would have to be degraded
togetherwith the substrate (figure 3a). Recentwork hasdemon-
strated that the proteasome is, indeed, capable of degrading the
proximal ubiquitin along with the substrate [93,94]. Alterna-
tively, the serine/threonine monoubiquitination may serve a
signalling function (figure 3a).4.2. Non-lysine ubiquitination facilitates differential
regulation of substrate fate
The ability of a single substrate to (i) be ubiquitinated on
more than one type of amino acid residue and (ii) potentially
require different E2/E3 combinations for isopeptide,
hydroxyester or thioester ubiquitin conjugation creates
many regulatory possibilities. The fact that these three bond
types have different inherent stabilities, with isopeptide
being the strongest and thioester the most labile, also presents
options for regulation based on the dynamics of ubiquitina-
tion versus deubiquitination, be it chemical or enzymatic
[24]. Examples of how non-canonical ubiquitination could
contribute to substrate regulation are described herein.
The cellular level of the neurogenin (Ngn) transcription
factors is regulated in opposing fashion by either binding to
a partner E protein, in which case Ngn is stable and active,
or, alternatively, being rapidly degraded by the proteasome
[95]. Ngn levels may also be regulated in part by phosphoryl-
ation, as Ngns are partially stabilized by cyclin-dependent
kinase inhibitors. Inappropriate stabilization of Ngns corre-
lates with promotion of neurogenesis, highlighting the
importance of its careful regulation. As such, it is perhaps
not surprising that Ngns are promiscuous ubiquitination sub-
strates that can be modified on the N-terminus as well as on
internal lysine, cysteine or serine/threonine residues. All
modifications were not, however, equally efficient at support-
ing degradation. For Ngn3, removing only lysine residues
had a dramatic effect on half-life while removing only
cysteines resulted in no significant difference [42]. By con-
trast, the rapid degradation of Ngn2 in mitotic extract was
similarly compromised by the absence of either lysines or
cysteines [41]. Interestingly, there was no effect of cysteine
mutation on Ngn2 stability in interphase extract, suggesting
that the ubiquitination of cysteines may be used, perhaps in
a cell cycle-dependent manner, as a stability regulation
mechanism [41].
Studies of MHC-I HC demonstrated that lysine residues
or serine/threonine residues could support its ubiquitination
and ERAD. The viral mK3 ligase, however, showed a prefer-
ence for serine/threonine residues even when lysines were
available [27,28] (§2.1.1). On the other hand, the cellular E3
ligase HRD1, while able to ubiquitinate MHC-I HC on both
lysine and serine/threonine residues, prefers lysine [36].
This suggests that, under normal circumstances, HRD1 may
use lysine to turn over MHC-I HC at a rate appropriate to
the needs of the cell, but upon viral infection MHC-I HC
degradation is inappropriately upregulated by targeted ubi-
quitination on serine/threonine residues by mK3. The
ability of the viral ligase to act with a cellular E2, Ube2J2
[28], to perform non-canonical ubiquitination thus acts to
misregulate MHC-I expression at the cell surface.
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12The studies of peroxisomal systems provide an excellent
view into howdifferent combinations of E2s, E3s and target resi-
dues for ubiquitination can direct the same protein to, for
example, the alternative fates of recycling/reuse or destruction
(figure 2). As described in §2.4.2, peroxisome import receptors
may be stably polyubiquitinated on lysine and targeted for pro-
teasome-mediated degradation; this is thought to serve a quality
control function. Monoubiquitination on a conserved cysteine
residue, on the other hand, acts as a transient signal to permit
another round of receptor export, cargo binding and return.
The identities of the relevant E2s and E3s for each type of
ubiquitination have been worked out and are distinct. Thus,
the two opposing fates of peroxisome transport receptors are
normally governed by which residues are used for ubiquitina-
tion, and by the specific E2(s)/E3(s) involved. An intriguing
experiment in which the conserved cysteine was replaced
with a lysine demonstrated that the Pex5 receptor was still ubi-
quitinated and, importantly, still able to function correctly;
however, its steady-state levels were dramatically reduced
[80]. This is likely due to the increased stability of the isopeptide
linkage to lysine, which persists and becomes polyubiquiti-
nated, targeting excessive amounts of Pex5 for proteasomal
degradation (figure 2b(ii)). As perturbations in Pex5 levels
would affect peroxisome homeostasis, which is linked to
numerous human disease states, the importance of correctly
regulating Pex5 levels is clear [96]. This highlights the critical
nature not only of having an amino acid capable of accepting
ubiquitin at a specific position, but also that it must support
both proper function and proper regulation of the target
protein. In keeping with this, the replacement of the conserved
cysteinewith serine preventedmonoubiquitination, release and
recycling of Pex5 and instead resulted in its membrane reten-
tion, polyubiquitination and degradation (figure 2b(iii)) [50].
Yet another way in which the steady-state levels of sub-
strates ubiquitinated on varying amino acids could be
regulated is by the presence or absence of ubiquitin hydro-
lases capable of acting upon them. As mentioned above,very little is yet known about the DUBs for non-canonical
ubiquitin conjugates. It has been shown, however, that the
S. cerevisiae ubiquitin-specific protease Usp15, which localizes
partially to peroxisomes, can act upon poly- or monoubiqui-
tinated Pex5, implying that it can attack both isopeptide and
thioester ubiquitin conjugates [97]. Furthermore, researchers
using a biochemical approach identified mammalian Usp9X
(homologous to Usp15) as a DUB for cysteine monoubiquiti-
nated Pex5. Again, however, this activity was not specific to
thioester linkages as the mutation of the conserved cysteine
to lysine still resulted in monoubiquitinated populations of
Pex5 that were acted upon by Usp9X [98]. The identification
of DUBs capable of acting upon hydroxyester linkages would
illuminate additional mechanisms for substrate regulation
(figure 3b) and argue against the proposal that serine/threo-
nine ubiquitination serves as a commitment to degradation.5. Concluding remarks
The steady increase in documented cases of non-lysine ubi-
quitination in recent years testifies to the cell biological
importance of the process. Non-lysine ubiquitination takes
place in different organisms, at various cellular locations,
and regulates a wide range of cellular processes. Moreover,
non-lysine ubiquitination should not be seen merely as a
‘supplement’ to lysine ubiquitination for lysine-free pro-
teins since ample evidence shows that certain E2/E3 pairs
preferentially ubiquitinate non-lysine residues.
Despite the growing awareness of the importance of non-
lysine ubiquitination many open questions exist. It will thus
be interesting to learn whether further examples of non-
lysine ubiquitination in cellular signalling, in addition to
the regulation of peroxisomal proteins, exist. In some cases
of RING-type E3-mediated non-lysine ubiquitination, serine
seems to be preferred over threonine. While the intrinsic
activity of the involved E2s may govern serine versus
royalsocietypublishing.org/journal/rsob
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13threonine preference, the underlying cause is still unclear. It
is also unresolved to which extent the position and local
environment of the ubiquitinated residue plays a role in
determining ubiquitination efficiency. To date, these ques-
tions have only been addressed in a few cases [33,99,100].
The following questions, among others, also remain unan-
swered. Is there competition for or cross-talk between
serine/threonine ubiquitination and phosphorylation? Does
cysteine ubiquitination compete with the many possible
modifications known to take place on cysteine side chains?
Both scenarios present even greater opportunities for regulat-
ory control. Does MYCBP2 constitute a lone example of an E3
ligase with non-lysine substrate specificity or are we in for
more surprises? What structural and biochemical features
determine intrinsic reactivity of E2 enzymes towards non-
lysine residues and how are they activated by their cognate
E3s? Do DUBs capable of hydrolysing hydroxyester bonds
exist?
Answering certain of these questions will necessitate the
development of better experimental tools to determine sites
of cellular non-lysine ubiquitination. While alkaline treatment
(for serine/threonine ubiquitination) or reduction (cysteine
ubiquitination) as well as mutational analysis are informative
strategies, high-resolution methods are needed to determine
specific sites of ubiquitination. Here, MS would be the
method of choice, but unfortunately has been unsuccessful in
certain cases [35,46], potentially due to the labile nature of the
hydroxyester bond. However, it is encouraging that recent
investigations have been more successful in employing MS
for the identification of serine ubiquitination [37,39]. To date,
global analyses of the ubiquitome have successfully enrichedsamples for ubiquitinated lysine residues through the use of
antibodies specifically raised against a protein antigen contain-
ing diglycine-modified lysines (anti-K-ε-GG; [101]). The
generation of antibodies that serve this purpose for ubiquitin-
modified serines, threonines and cysteines would provide a
means to examine how pervasive non-lysine ubiquitination
may be.
When surveying the literature on non-lysine ubiquitina-
tion it becomes apparent that the vast majority of studies
often discovered serine, threonine or cysteine ubiquitination
fortuitously during the course of investigating a specific
protein. On the contrary, few studies have investigated non-
lysine ubiquitination per se with the goal of learning more
about the molecular mechanism of the process itself. With
the information now available, it will next be critical to ask
targeted questions that examine the molecular mechanisms
of non-lysine ubiquitination in a cellular context. In parallel,
it will be essential to undertake biochemical and structural
investigations of the central E2 and E3 enzymes implicated
in this process, both in isolation and together. Perhaps we
can then better understand how they cooperate in performing
their functions and gain molecular insight at the atomic level
into the mechanisms of non-lysine ubiquitination.Data accessibility. This article does not contain any additional data.
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